{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:25:49Z","timestamp":1793330749561,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.lungcan.2023.107353","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T01:52:11Z","timestamp":1692582731000},"page":"107353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer"],"prefix":"10.1016","volume":"184","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107353_b0005","doi-asserted-by":"crossref","first-page":"iv1-iv21","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.06.016","article-title":"Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection","volume":"129","author":"Banna","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lungcan.2023.107353_b0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","article-title":"Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy","volume":"52","author":"Osmani","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.lungcan.2023.107353_b0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107353_b0025","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"38","author":"Hanna","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.689132","article-title":"The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2023.107353_b0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fonc.2015.00202","article-title":"Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data","volume":"5","author":"Ott","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0040","doi-asserted-by":"crossref","unstructured":"M. Terme, S. Pernot, E. Marcheteau, F. Sandoval, N. Benhamouda, O. Colussi, et al., VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer, Cancer Res. 73 (2013) 539-549. 10.1158\/0008-5472.can-12-2325.","DOI":"10.1158\/0008-5472.CAN-12-2325"},{"key":"10.1016\/j.lungcan.2023.107353_b0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107353_b0050","first-page":"338","article-title":"Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma, Liver","volume":"9","author":"Deng","year":"2020","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.lungcan.2023.107353_b0055","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107353_b0060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"issue":"4","key":"10.1016\/j.lungcan.2023.107353_b0070","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2023.107353_b0075","first-page":"551","article-title":"Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303, Thorac","volume":"10","author":"Si","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2023.107353_b0080","unstructured":"[Chinese expert consensus on Anlotinib Hydrochloride for advanced lung cancer (2020 edition)], Zhonghua Zhong Liu Za Zhi. 42 (2020) 807-816. 10.3760\/cma.j.cn112152-20200721-00669."},{"key":"10.1016\/j.lungcan.2023.107353_b0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2021.08.006","article-title":"Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study","volume":"160","author":"Zhou","year":"2021","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2023.107353_b0090","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0095","doi-asserted-by":"crossref","first-page":"A200","DOI":"10.1158\/1535-7163.TARG-17-A200","article-title":"Abstract A200: CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38\/H-11 murine colon and A375 human melanoma animal models","volume":"17","author":"Wei","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2023.107353_b0100","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.2021.39.3_suppl.292","article-title":"Anlotinib plus TQB2450 in patients with advanced refractory biliary tract cancer (BTC): An open-label, dose-escalating, and dose-expansion cohort of phase Ib trial","volume":"39","author":"Zhou","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2023.107353_b0105","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1200\/JCO.2021.39.15_suppl.1074","article-title":"A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer","volume":"39","author":"Wang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0110","doi-asserted-by":"crossref","unstructured":"C.Y. Lan, J. Zhao, F. Yang, Y. Xiong, R. Li, Y. Huang, et al., Anlotinib in Combination with TQB2450 in Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer (ACTION): A Multicenter, Single-Arm, Open-Label, Phase 1b Trial.Available at SSRN: https:\/\/ssrn.com\/abstract=3987490 or http:\/\/dx.doi.org\/10.2139\/ssrn.3987490. (2021).","DOI":"10.2139\/ssrn.3987490"},{"key":"10.1016\/j.lungcan.2023.107353_b0115","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1016\/j.annonc.2020.08.646","article-title":"532MO A phase Ib study of TQB2450 in combination with anlotinib in patients with advanced solid tumour","volume":"31","author":"Cheng","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0120","unstructured":"VENTANA PD-L1 (SP263) Assay (CE IVD): Tucson, AZ: Ventana Medical Systems, Inc; 2018 [Available from: https:\/\/diagnostics.roche.com\/gb\/en\/products\/tests\/ventana-pd-l1-_sp263-assay2.html."},{"key":"10.1016\/j.lungcan.2023.107353_b0125","doi-asserted-by":"crossref","unstructured":"H.S. Rugo, S. Loi, S. Adams, P. Schmid, A. Schneeweiss, C.H. Barrios, et al., PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer, J Natl Cancer Inst. 113 (2021) 1733-1743. 10.1093\/jnci\/djab108.","DOI":"10.1093\/jnci\/djab108"},{"key":"10.1016\/j.lungcan.2023.107353_b0130","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.breast.2021.11.003","article-title":"Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer","volume":"60","author":"Noske","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.lungcan.2023.107353_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107353_b0140","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1101\/gr.145144.112","article-title":"The transcriptional landscape and mutational profile of lung adenocarcinoma","volume":"22","author":"Seo","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.lungcan.2023.107353_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00595-017-1497-7","article-title":"Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy","volume":"48","author":"Saito","year":"2018","journal-title":"Surg. Today"},{"key":"10.1016\/j.lungcan.2023.107353_b0150","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2016.12.041","article-title":"Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges","volume":"78","author":"Giroux Leprieur","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107353_b0155","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial","volume":"14","author":"Wu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0160","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.lungcan.2023.107353_b0165","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107353_b0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107353_b0175","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejca.2020.06.007","article-title":"Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric\/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia\/b study (JVDJ)","volume":"137","author":"Bang","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107353_b0180","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0185","doi-asserted-by":"crossref","unstructured":"G. Gao, J. Zhao, S. Ren, Y. Wang, G. Chen, J. Chen, et al., Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer, Ann Transl Med. 10 (2022) 441. 10.21037\/atm-21-4792.","DOI":"10.21037\/atm-21-4792"},{"key":"10.1016\/j.lungcan.2023.107353_b0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0195","doi-asserted-by":"crossref","unstructured":"Y. Su, B. Luo, Y. Lu, D. Wang, J. Yan, J. Zheng, et al., Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma, Clin Cancer Res. 28 (2022) 793-809. 10.1158\/1078-0432.Ccr-21-2241.","DOI":"10.1158\/1078-0432.CCR-21-2241"},{"key":"10.1016\/j.lungcan.2023.107353_b0200","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","article-title":"Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer","volume":"69","author":"Yang","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lungcan.2023.107353_b0205","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lungcan.2023.107353_b0210","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6195","article-title":"Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K\/AKT signaling can be reversed by anlotinib","author":"Gao","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2023.107353_b0215","first-page":"2300141","article-title":"Anlotinib Combined with Anti-PD1 Potentiates Anti-Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming","author":"Zou","year":"2023","journal-title":"n\/a"},{"issue":"21","key":"10.1016\/j.lungcan.2023.107353_b0220","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107353_b0225","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions","volume":"24","author":"Xia","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2023.107353_b0230","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3892\/ol.2020.11685","article-title":"Anlotinib as a molecular targeted therapy for tumors","volume":"20","author":"Gao","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.lungcan.2023.107353_b0235","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/JTO.0b013e3182199c03","article-title":"Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials","volume":"6","author":"Soo","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107353_b0240","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/sj.bjc.6604721","article-title":"Emerging ethnic differences in lung cancer therapy","volume":"99","author":"Sekine","year":"2008","journal-title":"Br. J. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:07:15Z","timestamp":1759237635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223008917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":48,"alternative-id":["S0169500223008917"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107353","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107353"}}